Overall a lousy day in the market. Genentech (DNA) tops the largest percentage gainers today with news about a new possible treatment for Colon and Rectal Cancer. Advanced colon and rectal cancer has a rather dismal prognosis and we all know people who have succumbed to the disease. Anyhow Genentech has a new drug called AVASTIN which along with traditional chemotherapy has successfully extended the lifespan of individuals in their study who have this life-threatening illness.
A nice coincidence for us is that Genentech FITS our protocol...last quarter (ending 3/3103), per our cnn.money site, revenues rose 29% (!) to $768.6 Million, net income rose 59% to $151.5 Million.(!)...
Looking at the past 5 years, as we like to do around here, we find that the revenue has increased from $1.2 billion in 1998, 1.4 billion in 1999, 1.7 billion in 2000, 2.2 billion in 2001, and 2.7 billion in 2002. Extrapolating this latest quarter (x4) gives us over 3.0 billion for 2003. The consistency of the revenue growth is impressive.
The last four quarters as reported in Morningstar (prior to the CURRENT quarter noted above), we find that revenues increased by 13.59%, 26.45%, 21.40%, and 29.69%....and the latest quarter up by 29% as well. Cash flow has improved...from 81 million positive in 2000, to 267 million in 2001, and 265 million in 2002 the latest year reported.
So at the moment (12:05 pm CST), stock is at $53.04 up $15.14 (WOW), p/e is a bit steep (to say the least) at 212.40....yikes....but otherwise this stock fits the bill....would add a position in my own portfolio (I do not own any shares nor does anyone in my family)...but I do not have a stock that needs to be sold due to a gain....but this is one for the list. Good luck investing. Bob
Posted by bobsadviceforstocks at 12:09 PM CDT | Post Comment | Permalink